Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Do analysts prefer SNY or AZN?

Sanofi presently has a consensus price target of $57.50, suggesting a potential upside of 20.52%. AstraZeneca has a consensus price target of $89.75, suggesting a potential upside of 37.34%. Given AstraZeneca's higher possible upside, analysts plainly believe AstraZeneca is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
AstraZeneca	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

Is SNY or AZN a better dividend stock?

Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 3.1%. AstraZeneca pays an annual dividend of $0.98 per share and has a dividend yield of 1.5%. Sanofi pays out 75.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca pays out 46.9% of its earnings in the form of a dividend.

Do institutionals and insiders hold more shares of SNY or AZN?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is SNY or AZN more profitable?

AstraZeneca has a net margin of 12.68% compared to Sanofi's net margin of 9.96%. AstraZeneca's return on equity of 30.01% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	9.96%	27.45%	15.79%
AstraZeneca	12.68%	30.01%	11.42%

Does the media prefer SNY or AZN?

In the previous week, Sanofi had 8 more articles in the media than AstraZeneca. MarketBeat recorded 24 mentions for Sanofi and 16 mentions for AstraZeneca. Sanofi's average media sentiment score of 0.72 beat AstraZeneca's score of 0.47 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	11 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AstraZeneca	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings & valuation, SNY or AZN?

AstraZeneca has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$48.86B	2.48	$5.84B	$1.96	24.34
AstraZeneca	$51.21B	3.96	$5.96B	$2.09	31.27

Does the MarketBeat Community prefer SNY or AZN?

AstraZeneca received 11 more outperform votes than Sanofi when rated by MarketBeat users. However, 61.25% of users gave Sanofi an outperform vote while only 58.82% of users gave AstraZeneca an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 49 61.25%	Underperform Votes 31 38.75%
AstraZeneca	Outperform Votes 60 58.82%	Underperform Votes 42 41.18%

Which has more risk & volatility, SNY or AZN?

Sanofi has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Summary

AstraZeneca beats Sanofi on 13 of the 21 factors compared between the two stocks.